MESOBLAST LTD - RYONCIL QUARTERLY NET REVENUE RISES TO US$30.3M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MESO?
Source: moomoo
- Company Overview: Mesoblast Ltd has reported a revenue increase for the quarter, reaching $30.3 million.
- Financial Performance: The rise in revenue indicates positive growth and performance for the company during the specified period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MESO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.870
Low
35.00
Averages
35.00
High
35.00
Current: 14.870
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mesoblast Receives FDA Approval for DMD Clinical Trial
- Clinical Trial Approval: Mesoblast announced that it has received FDA IND clearance to directly proceed with a registrational clinical trial of Ryoncil® for Duchenne muscular dystrophy (DMD), potentially benefiting approximately 15,000 children in the U.S., marking a significant advancement in addressing this severe condition.
- Trial Design: The trial will randomize 76 patients aged 5 to 9 years to receive either Ryoncil® (7 infusions of 2 x 106 cells/kg) or placebo, with the primary endpoint being time-to-stand at nine months, aligning with FDA approval standards to validate Ryoncil®'s efficacy.
- Partnership Engagement: Mesoblast is collaborating with Parent Project Muscular Dystrophy (PPMD) to enhance patient identification and trial awareness through proactive community engagement, ensuring eligible patients can participate in the trial in a timely manner, thereby accelerating clinical research progress.
- Strategic Implications: This trial is not only based on Ryoncil®'s proven safety in children and efficacy in DMD preclinical models but also aims to intervene in the inflammatory mechanisms of DMD, potentially altering disease progression and enhancing Mesoblast's market position in cellular therapies.
See More
Mesoblast Receives FDA Clearance for DMD Clinical Trial
- Clinical Trial Approval: Mesoblast Limited announced that it has received IND clearance from the FDA to directly proceed with a registrational clinical trial evaluating Ryoncil (Remestemcel-L-rknd) for Duchenne muscular dystrophy (DMD), marking a significant advancement in the biotechnology sector.
- Patient Scale and Design: The trial will randomize 76 patients aged 5 to 9 years to receive either Ryoncil or placebo in addition to standard care, with 7 infusions of 2 × 10^6 cells/kg, aiming to significantly advance clinical research in DMD treatment.
- Market Potential: Ryoncil is the first FDA-approved mesenchymal stromal cell product, with projected revenues nearing $100 million in its first year post-launch in 2025, indicating strong market potential for treating both pediatric acute graft-versus-host disease (SR-aGvHD) and DMD.
- Collaboration and Community Engagement: Mesoblast is collaborating with Parent Project Muscular Dystrophy (PPMD) to enhance patient identification and trial awareness through proactive community engagement, further strengthening its strategic positioning in the DMD space.
See More
MESOBLAST GETS FDA IND APPROVAL TO INITIATE REGISTRATIONAL TRIAL FOR RYONCIL
- Regulatory Approval: Mesoblast has received clearance from the FDA to proceed with a registration trial for the approval of Ryoncil.
- Next Steps: The company will now move forward with the trial aimed at obtaining regulatory approval for the treatment.
See More
MESOBLAST LTD - FDA Approves RYONCIL IND for DMD Registration Trial
Company Overview: Mesoblast Ltd is a biotechnology company focused on developing innovative cell-based therapies for various medical conditions.
Regulatory Update: The company has received clearance from the FDA to proceed with a registration trial for its product in the field of regenerative medicine.
Trial Details: The upcoming trial will assess the efficacy and safety of Mesoblast's therapy in patients with specific medical conditions.
Market Impact: This regulatory approval is expected to enhance Mesoblast's market position and potentially lead to significant advancements in treatment options.
See More
Mesoblast Reports Ryoncil Sales Data for Q2 2026
- Sales Data Highlights: Mesoblast reported net sales of $30.3 million for its cell therapy Ryoncil in Q2 2026, with strong sales in February and March offsetting the holiday seasonality impact in January, indicating robust market demand for the product.
- Annual Sales Performance: Ryoncil's revenue has approached $100 million in its first year post-launch, suggesting increasing market acceptance in the treatment of acute graft-versus-host disease (SR-aGVHD), which may lay a solid foundation for future growth.
- Quarterly Growth Trend: Mesoblast reported total revenue of $35.1 million for Ryoncil in the December quarter, reflecting approximately 60% growth from the previous quarter, showcasing the effectiveness of the company's marketing and sales strategies.
- Future Strategic Planning: Mesoblast is set to outline its late-stage pipeline plans and growth strategy for Ryoncil during its inaugural R&D Day, expected to provide investors with clearer business prospects and development directions.
See More
Mesoblast Reports Strong Ryoncil® Sales Growth
- Strong Sales Performance: Mesoblast reported net sales of $30.3 million for Ryoncil® (remestemcel-L-rknd) for the quarter ending March 31, 2026, with robust sales in February and March offsetting January's seasonal downturn, indicating sustained market demand for the product.
- Annual Revenue Approaching $100 Million: Since its launch, Ryoncil® has generated nearly $100 million in its first year, significantly strengthening Mesoblast's balance sheet and providing funding for label extensions and late-stage blockbuster programs, underscoring the company's leadership in cellular therapies.
- FDA-Approved Innovative Therapy: Ryoncil® is the first FDA-approved mesenchymal stromal cell product specifically for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD), giving the company a unique competitive edge in the market.
- Future Strategic Planning: Mesoblast will host its inaugural R&D Day on April 8, 2026, in New York, where it will outline the growth strategy for Ryoncil® and its robust late-stage product pipeline, further solidifying its position in the cellular therapy market.
See More
Mesoblast Receives FDA Approval for DMD Clinical Trial
- Clinical Trial Approval: Mesoblast announced that it has received FDA IND clearance to directly proceed with a registrational clinical trial of Ryoncil® for Duchenne muscular dystrophy (DMD), potentially benefiting approximately 15,000 children in the U.S., marking a significant advancement in addressing this severe condition.
- Trial Design: The trial will randomize 76 patients aged 5 to 9 years to receive either Ryoncil® (7 infusions of 2 x 106 cells/kg) or placebo, with the primary endpoint being time-to-stand at nine months, aligning with FDA approval standards to validate Ryoncil®'s efficacy.
- Partnership Engagement: Mesoblast is collaborating with Parent Project Muscular Dystrophy (PPMD) to enhance patient identification and trial awareness through proactive community engagement, ensuring eligible patients can participate in the trial in a timely manner, thereby accelerating clinical research progress.
- Strategic Implications: This trial is not only based on Ryoncil®'s proven safety in children and efficacy in DMD preclinical models but also aims to intervene in the inflammatory mechanisms of DMD, potentially altering disease progression and enhancing Mesoblast's market position in cellular therapies.
See More
Mesoblast Receives FDA Clearance for DMD Clinical Trial
- Clinical Trial Approval: Mesoblast Limited announced that it has received IND clearance from the FDA to directly proceed with a registrational clinical trial evaluating Ryoncil (Remestemcel-L-rknd) for Duchenne muscular dystrophy (DMD), marking a significant advancement in the biotechnology sector.
- Patient Scale and Design: The trial will randomize 76 patients aged 5 to 9 years to receive either Ryoncil or placebo in addition to standard care, with 7 infusions of 2 × 10^6 cells/kg, aiming to significantly advance clinical research in DMD treatment.
- Market Potential: Ryoncil is the first FDA-approved mesenchymal stromal cell product, with projected revenues nearing $100 million in its first year post-launch in 2025, indicating strong market potential for treating both pediatric acute graft-versus-host disease (SR-aGvHD) and DMD.
- Collaboration and Community Engagement: Mesoblast is collaborating with Parent Project Muscular Dystrophy (PPMD) to enhance patient identification and trial awareness through proactive community engagement, further strengthening its strategic positioning in the DMD space.
See More
MESOBLAST GETS FDA IND APPROVAL TO INITIATE REGISTRATIONAL TRIAL FOR RYONCIL
- Regulatory Approval: Mesoblast has received clearance from the FDA to proceed with a registration trial for the approval of Ryoncil.
- Next Steps: The company will now move forward with the trial aimed at obtaining regulatory approval for the treatment.
See More
MESOBLAST LTD - FDA Approves RYONCIL IND for DMD Registration Trial
Company Overview: Mesoblast Ltd is a biotechnology company focused on developing innovative cell-based therapies for various medical conditions.
Regulatory Update: The company has received clearance from the FDA to proceed with a registration trial for its product in the field of regenerative medicine.
Trial Details: The upcoming trial will assess the efficacy and safety of Mesoblast's therapy in patients with specific medical conditions.
Market Impact: This regulatory approval is expected to enhance Mesoblast's market position and potentially lead to significant advancements in treatment options.
See More
Mesoblast Reports Ryoncil Sales Data for Q2 2026
- Sales Data Highlights: Mesoblast reported net sales of $30.3 million for its cell therapy Ryoncil in Q2 2026, with strong sales in February and March offsetting the holiday seasonality impact in January, indicating robust market demand for the product.
- Annual Sales Performance: Ryoncil's revenue has approached $100 million in its first year post-launch, suggesting increasing market acceptance in the treatment of acute graft-versus-host disease (SR-aGVHD), which may lay a solid foundation for future growth.
- Quarterly Growth Trend: Mesoblast reported total revenue of $35.1 million for Ryoncil in the December quarter, reflecting approximately 60% growth from the previous quarter, showcasing the effectiveness of the company's marketing and sales strategies.
- Future Strategic Planning: Mesoblast is set to outline its late-stage pipeline plans and growth strategy for Ryoncil during its inaugural R&D Day, expected to provide investors with clearer business prospects and development directions.
See More
Mesoblast Reports Strong Ryoncil® Sales Growth
- Strong Sales Performance: Mesoblast reported net sales of $30.3 million for Ryoncil® (remestemcel-L-rknd) for the quarter ending March 31, 2026, with robust sales in February and March offsetting January's seasonal downturn, indicating sustained market demand for the product.
- Annual Revenue Approaching $100 Million: Since its launch, Ryoncil® has generated nearly $100 million in its first year, significantly strengthening Mesoblast's balance sheet and providing funding for label extensions and late-stage blockbuster programs, underscoring the company's leadership in cellular therapies.
- FDA-Approved Innovative Therapy: Ryoncil® is the first FDA-approved mesenchymal stromal cell product specifically for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD), giving the company a unique competitive edge in the market.
- Future Strategic Planning: Mesoblast will host its inaugural R&D Day on April 8, 2026, in New York, where it will outline the growth strategy for Ryoncil® and its robust late-stage product pipeline, further solidifying its position in the cellular therapy market.
See More
